Ligand Pharmaceuticals (LGNDZ) Long-Term Deferred Tax (2016 - 2025)
Ligand Pharmaceuticals (LGNDZ) has disclosed Long-Term Deferred Tax for 14 consecutive years, with $8.3 million as the latest value for Q4 2025.
- Quarterly Long-Term Deferred Tax rose 11490.28% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 11490.28% year-over-year, with the annual reading at $8.3 million for FY2025, 11490.28% up from the prior year.
- Long-Term Deferred Tax hit $8.3 million in Q4 2025 for Ligand Pharmaceuticals, down from $9.5 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $35.7 million in Q4 2021 to a low of $72000.0 in Q4 2024.
- Historically, Long-Term Deferred Tax has averaged $14.3 million across 5 years, with a median of $8.5 million in 2022.
- Biggest five-year swings in Long-Term Deferred Tax: tumbled 99.09% in 2024 and later skyrocketed 12112.82% in 2025.
- Year by year, Long-Term Deferred Tax stood at $35.7 million in 2021, then tumbled by 76.13% to $8.5 million in 2022, then tumbled by 97.49% to $214000.0 in 2023, then plummeted by 66.36% to $72000.0 in 2024, then skyrocketed by 11490.28% to $8.3 million in 2025.
- Business Quant data shows Long-Term Deferred Tax for LGNDZ at $8.3 million in Q4 2025, $9.5 million in Q3 2025, and $829000.0 in Q2 2025.